Peptide Works

Peptide Works began with a problem that anyone working with research peptides will recognise. A researcher orders a compound, waits, receives it, and then has to spend the first part of the project working out whether what arrived is actually what was ordered. Purity figures quoted without evidence. Certificates of analysis that never appear, or appear months later, or refer to a batch that isn't the one in the vial. Vials that arrive warm after four days in a courier depot. Support inboxes that go quiet the moment payment clears.

None of that is exotic. It is the ordinary background noise of buying research materials, and researchers have largely learned to work around it. They order early to absorb the delays. They order extra to absorb the losses. They run their own confirmatory checks on material that was supposed to arrive pre-verified, burning time and reagents to establish something the supplier should have established already. Some of them keep informal notes on which vendors can be trusted with which compounds, passed between colleagues in the way that useful, unofficial knowledge usually travels.

We did not think any of that should be necessary.

So Peptide Works was built around a fairly narrow promise: that the compound in the vial is what the label says it is, that we can show you the evidence, and that if something is wrong you will be able to speak to a person who will fix it. That is not a dramatic mission statement. It fits in a sentence and it does not make for a memorable slogan. It is, however, one we can actually keep, and keeping it consistently has turned out to matter more to our customers than anything more ambitious we could have written on a homepage.

There is a particular kind of supplier that grows quickly in this space and then quietly gets worse. The catalogue expands faster than the quality controls. Testing becomes a sample-based exercise rather than a batch-based one. Support gets outsourced to a team that has never seen a certificate of analysis. Margins get protected by shaving cost off packaging, which is invisible right up until the day it isn't. We have watched this happen to companies that were, at one point, genuinely good.

We have tried to build the opposite. Growth at Peptide Works is deliberately constrained by what we can verify. If we cannot source a compound at a purity we are prepared to defend in writing, we do not list it, regardless of how much demand there is. If a new supplier's material does not survive our incoming checks, we do not use them, regardless of price. These are not difficult decisions in principle. They are only difficult in the moment, when the order is waiting and the alternative is easy. We make them anyway, because the entire value of what we do collapses the first time we don't.

Today we ship to researchers in most countries. We maintain one of the broader research peptide catalogues available. And we still answer our own support messages.

Our mission is to support scientific work by supplying research peptides of consistent, verifiable quality, backed by service that does not disappear after dispatch.

Research is slow and expensive enough on its own. Grant cycles are finite. Bench time is finite. The window in which a research team has funding, personnel, equipment access, and a clear question all lined up at once is narrower than people outside the field tend to assume, and it does not reopen conveniently. When a supplier introduces uncertainty into that window — about purity, about identity, about whether an order will arrive at all — the uncertainty does not stay contained. It propagates into the work.

Consider what an unreliable input actually costs. A batch comes in below its stated purity. The experiment produces a result that does not match the literature. The research team now has a genuine problem: is the finding real, or is it an artefact of the material? They cannot know without investigating, so they investigate. That means re-running the assay, sourcing a second batch, possibly running their own analytical characterisation. Weeks disappear. And the maddening part is that at the end of it, the most likely answer is the least interesting one — the compound was not what it was supposed to be, and the last month was spent proving a supplier wrong rather than doing science.

Multiply that across a field and the cost is enormous. It is also almost entirely invisible, because it never appears in a paper. Nobody publishes the three months they lost to a bad lot.

We take the view that our job is to remove ourselves as a variable. What a research team is testing should be their hypothesis, not our supply chain. Every process we run — third-party verification, batch-level documentation, controlled storage, considered packing, staffed support — exists to serve that single objective. We are not trying to be interesting. We are trying to be boring in the specific way that a reliable instrument is boring: you stop thinking about it, and that is the whole point.

It follows from this that our mission is measured in things not happening. No unexplained variance between lots. No missing paperwork when an institution asks for it. No compound arriving degraded because someone treated a cold-chain shipment as ordinary freight. No researcher discovering, in the middle of a run, that the supplier is unreachable. Success for us looks like an absence of incident, sustained over years.

We want Peptide Works to be the supplier researchers reach for without having to think about it.

That sounds modest, and it is meant to. There is no clever way to become the default choice in a field where the customers are, by profession, sceptics. Trust here is not won with a campaign, a rebrand, or a well-placed superlative. Researchers are trained to discount claims that are not supported, and they apply that training to their vendors as readily as to a manuscript. This is entirely reasonable, and we would think less of them if they didn't.

Trust of this kind is won one order at a time, over years, by being correct about small things repeatedly. The certificate that arrives without having to be chased. The lot number that matches the record. The tracking link that works. The reply that comes back the same day and actually answers the question. Individually, none of these is worth mentioning. Collectively, over a long enough period, they are the only thing that matters.

So the vision is simply this: a researcher who has ordered from us three times should have no reason to consider a fourth supplier. The purity has held. The paperwork has been there. The parcel arrived when it was supposed to. And the one time something went wrong — because eventually something always goes wrong — we sorted it out without an argument, without a form, and without making them prove anything.

Beyond that, we want the standard we hold ourselves to become harder for others to avoid. Every-batch third-party testing is not universal in this industry. It should be. Batch-matched certificates of analysis available on request should be unremarkable rather than a selling point. Cold-chain compounds should be packed for the route they are actually taking. If enough suppliers operate this way, researchers stop having to keep informal lists of who can be trusted with what, and the whole field moves slightly faster. We are not naive about our influence, but we would rather compete by raising the floor than by finding somewhere else to cut.

Quality is where a peptide supplier either has a business or does not, so it is worth being specific about what we do rather than leaning on adjectives.

Independent Third-Party Testing

Every batch we sell is tested by an independent third-party laboratory. Not a sample of batches. Not the first batch of a new product line. Not a representative lot from six months ago that gets attached to everything shipped since. Every batch.

We do this deliberately, and at real cost to ourselves, because in-house testing asks the customer to take our word for it. Third-party testing does not. The laboratories we work with have no commercial interest in the result being flattering, which is exactly the point. They do not know what we would like the number to be, and if they did, it would not help them.

The distinction matters more than it might appear. A supplier testing its own material is not necessarily dishonest, but it is structurally conflicted, and it is operating without a check. Analytical methods have parameters, and parameters can be set generously. Chromatography can be run in ways that resolve impurities clearly or in ways that don't. A supplier under commercial pressure, testing itself, with no external review, is in a position where small accommodations are easy to make and impossible for anyone outside to detect. We removed ourselves from that position on purpose.

It also means that when a batch fails, it fails visibly, in a document, produced by a party who does not work for us. That gives us no room to talk ourselves into shipping it. This is a feature.

Purity Standards

Our standard is a minimum of 99% purity, verified by high-performance liquid chromatography. For more structurally complex sequences — longer chains, peptides with difficult secondary structure, compounds where synthesis and purification are genuinely harder — our floor is 98%.

That second threshold is not a loophole and we want to be clear about why it exists. Solid-phase peptide synthesis becomes measurably more difficult as chain length grows. Each coupling step is efficient but not perfect, and the small inefficiencies compound. Certain sequences aggregate on the resin. Certain residues are prone to side reactions. The result is that for some compounds, a 99% purity claim is not a mark of rigour — it is a mark of someone who has not looked carefully, or who is quoting a number that the analytical method was never capable of supporting. We would rather tell you honestly that a complex sequence sits at 98.4% than tell you what you want to hear.

We publish the real figure for the batch, not the target. If a batch tests at 99.2%, that is what the certificate says. It does not become “99%+” or “high purity” or any of the other formulations that exist to make a specific number sound like a general reassurance. We are not interested in rounding in our own favour, and researchers doing quantitative work need the actual figure anyway — if you are calculating concentrations, the difference between a stated 99% and an actual 98.6% is not academic.

Identity is confirmed alongside purity, typically by mass spectrometry, which establishes that the molecular mass of the material matches the expected mass for the sequence. This is not optional and it is not a formality. A pure compound that is the wrong compound is not a useful compound; it is a very clean way to ruin an experiment. Purity without identity confirmation tells you only that your material is consistently something.

Certificates of Analysis

A certificate of analysis is available for every product we sell, and it corresponds to the batch you actually received rather than to a representative batch from some point in the past.

This distinction is quietly one of the most important things on this page, because the second practice is widespread and it is very close to meaningless. A COA that does not correspond to the vial in your hand tells you what a different quantity of material looked like on a different day. It has the appearance of documentation without the function of it. Any supplier can produce one good batch, test it thoroughly, and hang that certificate on every subsequent shipment.

Ours are batch-matched. If you need the COA for a specific lot number, our team will send it to you, and it will be the document for that lot. This is a routine request and we treat it as one — no explanation of why you want it, no delay while somebody looks for it, no eventual reply saying it is not available. Many research institutions require batch-level documentation as a condition of use, and a supplier who cannot produce it on request is, for those customers, simply not a usable supplier.

Batch-to-Batch Consistency

Purity is the headline number, but consistency between lots is often what actually determines whether a supplier is workable over the life of a project.

A research programme that runs for two years will consume multiple batches of the same compound. If those batches differ meaningfully — in purity, in impurity profile, in residual content — then the material has introduced variance into a dataset that is supposed to be measuring something else. Worse, that variance is silent. It does not announce itself. It simply widens error bars, weakens effects, and makes results harder to reproduce, and the research team may never identify the cause.

We manage this by working with a stable set of synthesis sources rather than buying opportunistically from whoever is cheapest that quarter, by testing every batch against the same standard, and by holding documentation that lets us compare a new lot against the ones that preceded it. Where a batch deviates from the profile we expect, it does not ship simply because it clears the purity threshold. Meeting the number and matching the history are two different tests, and we apply both.

Stability, Storage, and Handling

Peptides are not robust materials. They are sensitive to temperature, to moisture, to light, and to time. A compound can leave a synthesis facility at 99.3% purity and arrive at a laboratory meaningfully degraded, and the certificate will still say 99.3% — because the certificate describes what the material was, not what it has since become. Everything that happens between those two points is the supplier's responsibility, and a great many suppliers behave as though it isn't.

Degradation is not usually dramatic. It is hydrolysis, oxidation, deamidation, aggregation — slow chemistry, driven by conditions, that a vial undergoes quietly. Lyophilised peptide is far more stable than peptide in solution, which is precisely why it is supplied lyophilised, but “more stable” is not “indefinitely stable” and it is certainly not “stable at any temperature you like.”

So we store our inventory under controlled conditions appropriate to each compound. Lyophilised material is kept cold and dry, protected from light, in conditions that are monitored rather than assumed. Stock is rotated so that older lots move first rather than sitting at the back of a shelf while newer material is picked from the front — a mundane discipline that is skipped constantly and that quietly determines how old the average vial a customer receives actually is.

We would rather delay a dispatch by a day to pack it properly than hit a shipping target and send out something that will degrade in a warehouse. Speed is a service; integrity of the material is the product. When those two things conflict, it is not a close call.

Our catalogue is one of the more extensive available in the research peptide space, and we expand it steadily rather than in bursts. New compounds are added when we can source them at a purity we are prepared to stand behind, and not before. That sequencing is not negotiable, and it does mean we are occasionally slower than competitors to list something that researchers are asking about. We accept that trade. A compound listed before it can be verified is a liability wearing the costume of a product.

The range spans well-established research peptides that have been studied for decades alongside newer sequences that have only recently entered the literature. It includes short peptides and longer chains, single compounds and pre-prepared blends, and it covers the compounds that appear most frequently in current research alongside a long tail of less common sequences that are difficult to source elsewhere. Individual listings, including our SS-31 research peptide page, provide product-specific information for researchers reviewing the catalogue. That long tail is deliberately maintained even though it is commercially unglamorous, because a supplier who only stocks the twenty best-selling compounds is a supplier a research team will always have to supplement with somebody else.

Breadth has a practical value that is easy to underrate. A research group sourcing six compounds from four vendors is managing four lead times, four packing standards, four sets of documentation in four formats, and four separate opportunities for something to go missing in customs. Consolidating that into a single order with a single supplier and a single consistent standard of paperwork is not a small administrative convenience. It removes points of failure.

We also supply research peptides in a range of presentations. Alongside standard lyophilised vials, our catalogue includes pre-mixed formats, blended preparations, capsule presentations, and nasal spray presentations. Different research applications call for different formats, and we would rather offer a format than tell a research team to work around its absence.

All formats, without exception, are supplied strictly for laboratory research and development. Nothing in our catalogue is supplied for human or animal use, and the presentation format does not change that in any way. A compound presented in one physical form rather than another remains a research material governed by the same restrictions, and we would ask customers not to read anything into format availability that is not there.

If a compound you need is not listed, it is worth asking. We can often source it through the same channels and to the same standards we apply to everything else, and we would rather have that conversation than lose a customer to an unlisted product. Where we cannot source something to our standard, we will tell you that too, rather than obtain it from a source we do not trust and hope for the best.

We answer our own support messages, and we keep answering them after the parcel has been delivered.

That second part is where most suppliers quietly stop. An order is dispatched, the transaction closes, and as far as the seller is concerned the relationship is over. Post-delivery contact becomes a cost centre to be minimised — routed into a ticketing system, answered by someone with no product knowledge, resolved by attrition when the customer gives up. Everyone in this field has experienced it. Most have stopped expecting anything else.

We treat dispatch as roughly the halfway point.

If your parcel is delayed in customs, if a certificate of analysis is missing, if a lot number does not match your records, if a vial arrives damaged, if the packaging looks like it has had a hard journey, if you want to confirm a storage condition before you open something, if you simply want to know whether the batch you have now is from the same source as the batch you had six months ago — those are all entirely reasonable things to contact a supplier about, and we would rather you did. We would much rather answer a question early than deal with the consequences of a customer guessing.

Our team knows the products. When you ask a question about a compound, you are not talking to a general customer-service function reading from a card and hoping the phrasing of your question matches something in their script. That means technical queries are usually resolved in one exchange rather than four, and it means the person replying to you understands why the question matters rather than merely that it was asked.

Response times are something we hold ourselves to rather than something we advertise vaguely. We aim to reply to every enquiry within one working day, and in practice most are answered faster. Where a question requires us to check something with a laboratory or a source, we say so and give a realistic timeframe instead of leaving the message unanswered while we look into it. Silence is the single most common failure in customer support and it is entirely avoidable.

There are questions we will not answer, and it is fair to say so plainly here rather than leaving you to discover it. We do not provide dosing information, administration guidance, reconstitution protocols for use, or any advice relating to human or animal application. This is not evasiveness and it is not us being difficult. Our products are research materials, we supply them as research materials, and any question that presupposes another use is one we will decline — politely, but without exception and without a workaround. Researchers understand this immediately. It is part of operating in this field responsibly, and a supplier who does not hold that line is telling you something about how seriously it takes everything else.

We ship to researchers in most countries worldwide.

Orders are processed and dispatched promptly, and we send tracking as soon as it exists rather than when a batch of tracking numbers is uploaded at the end of the week. A tracking number issued three days after dispatch is not a tracking service; it is a receipt. If your parcel is moving, you should be able to see it moving.

Packaging is chosen for the compound and for the destination, not for our convenience. A two-day domestic transit and a fourteen-day international one with a customs inspection in the middle are not the same problem, and it is negligent to pack them as though they are. Cold-chain shipments are packed to hold temperature across the realistic worst case of their route — including the delays that international freight routinely produces, the weekend a parcel spends in a depot, and the inspection nobody scheduled. Packing to the advertised transit time rather than the plausible one is the single most common way that good material arrives bad.

Parcels are packed discreetly and labelled accurately. Vials are protected against the ordinary violence of freight handling, which is considerable and which no amount of “fragile” marking prevents.

International shipping is not entirely predictable, and we do not pretend otherwise. Customs holds happen. Carriers lose parcels. Weather closes routes. Depots make mistakes. Any supplier promising you that none of this will ever occur is either inexperienced or not being straight with you. What a supplier can control is what happens next — and this is where the difference between vendors becomes obvious.

We offer shipping protection so that when something goes wrong in transit, the loss does not simply land on the customer. Our team will work the problem with you: chasing the carrier, escalating where escalation is possible, and resolving the order. What we will not do is point at the tracking page, observe that the parcel left our facility in good order, and close the ticket. The parcel leaving our facility is not the same thing as the order being fulfilled, and treating it as such is a way of defining a problem out of existence rather than solving it. Full information about dispatch, delivery, transit issues, and returns is available in the Peptide Works shipping and returns policy.

Import requirements differ from country to country, and it remains the responsibility of the customer to know what may lawfully be imported into their jurisdiction for research purposes. We will tell you what we know and we will provide the documentation you need from our side. We cannot know your local regulations better than you do, and any supplier who implies otherwise is offering reassurance rather than information.

Consistency Over Claims

Anyone can make a strong claim once. Anyone can get one batch right, photograph one certificate, and build a marketing page around it. The difficulty is being the same on the four-hundredth order as on the first, when volume has grown, when the original team has expanded, when there is pressure on margin and a perfectly reasonable-sounding argument for cutting one corner that nobody would ever notice.

We would rather be reliably good than occasionally spectacular. Our processes are built for repeatability rather than for peak performance, and the standards are written down rather than held in the heads of whoever happens to be doing the work that day. This is deeply unglamorous. It is also the only thing that survives growth.

Evidence Over Assertion

If we say a batch is 99.1% pure, there is a document from an independent laboratory that says so, and you can have it.

We do not expect to be believed on the strength of our own marketing, and we do not think we should be. Our customers are professionally trained to demand evidence, and a supplier who asks them to suspend that instinct as a courtesy is asking for something they should not receive. Claims that cannot be evidenced do not appear on this website, which is why this page contains fewer superlatives than most and rather more specifics.

Transparency, Including When It Is Awkward

If a batch does not meet standard, it does not get sold — not discounted, not quietly listed as a lower grade, not held back for a customer we think will not check. It does not ship.

If a shipment is delayed, we tell you it is delayed rather than letting you discover it from a tracking page that has not updated in five days. If we make a mistake, we say so, correct it, and do not make you fight for the correction or produce evidence of our own error. If we do not know the answer to something, we say that instead of constructing something plausible.

This costs us money occasionally. A rejected batch is a write-off. A replaced shipment is a loss. It is still the cheaper option over any timeframe that matters, because the alternative — a customer who eventually works out that the material was not what we said it was — costs us that customer, everyone they talk to, and the only thing we actually sell.

Respect for the Work

Our customers are doing serious work under real constraints: funding, timelines, review, replication, and the ordinary difficulty of trying to find out something true. Most of them are not going to become famous for it. Much of it will not work.

We are aware of where we sit in that. We are not doing the science. We are supplying an input to it, and our entire ambition is to be one of the parts of that process that does not cause anybody trouble — that does not consume attention, generate correspondence, or introduce doubt. When a supplier becomes something a research team has to think about, the supplier has already failed.

Researchers tend to come to us for one of a few reasons, and they tend to stay for the same ones.

The purity holds. Batch after batch, the figure on the certificate is the figure in the vial. Consistency between lots is not a nice extra in research work; it is frequently the difference between a usable dataset and a wasted quarter. Our customers are not choosing us because one batch tested well. They are choosing us because eleven of them did.

The paperwork is there. A third-party certificate of analysis, matched to the batch, available on request without a negotiation, an explanation, or a two-week wait. If your institution requires batch-level documentation — and a great many do — you will have it, in a form that will satisfy them.

The catalogue is deep. Most orders can be consolidated with one supplier, in one shipment, with one set of paperwork and one standard of packing, rather than assembled from four vendors with four lead times and four different ideas about what adequate protection looks like.

The support is real. A person who knows the products, who replies within a working day, who understands the question rather than pattern-matching it, and who is still there after the parcel has arrived.

The pricing is honest. We are competitive, and we do not achieve it by cutting purity, skipping third-party testing on batches we think will probably be fine, or packing a cold-chain compound in a padded envelope and hoping the weather holds. Customers who want to review accepted payment methods and transaction details before ordering can consult the Peptide Works Payment Information page. Every one of those shortcuts is available to us and every one of them would improve our margin tomorrow. Good value in this field means paying a fair price for material you can rely on — not paying less for material you cannot, which is not a saving at all once you account for the experiment it ruins.

The shipping works. Global coverage, packing appropriate to the actual route, accurate tracking issued when it should be, and protection when transit goes wrong — followed by a team that treats a lost parcel as our problem to solve rather than yours to absorb.

None of these is a remarkable claim on its own. Together, held consistently over years, they are the entire reason our customers keep ordering, and we do not have or want any other reason.

If you have a question about a compound, a batch, a certificate of analysis, an order, or a shipment, our team is available and will respond.

If you need a peptide we do not currently list, tell us — it may well be something we can source to the same standard we hold everything else to. If you are considering placing a first order and want to see the documentation for a product before you commit, ask, and we will send it. We would rather have the conversation before you order than resolve a misunderstanding afterwards, and a customer who arrives with questions is a customer we would rather have than one who arrives with assumptions.